MicroRNA regulation of endothelial TREX1 reprograms the tumour microenvironment

Nature Communications

Volumn 7, Issue , 2016, Pages

  Wilson, RaeAnna ^a   Espinosa Diez, Cristina ^a   Kanner, Nathan ^a   Chatterjee, Namita ^a   Ruhl, Rebecca ^a   Hipfinger, Christina ^a   Advani, Sunil J ^b   Li, Jie ^c   Khan, Omar F ^d   Franovic, Aleksandra ^e   Weis, Sara M ^e   Kumar, Sushil ^a   Coussens, Lisa M ^a   Anderson, Daniel G ^d   Chen, Clark C ^c   Cheresh, David A ^e   Anand, Sudarshan ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Massachusetts Institute of Technology   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; MESSENGER RNA; MICRORNA; MICRORNA 103; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG; EXODEOXYRIBONUCLEASE; MIRN103 MICRORNA, HUMAN; PHOSPHOPROTEIN; SMALL INTERFERING RNA; THREE PRIME REPAIR EXONUCLEASE 1; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 6;

APOPTOSIS; CELLS AND CELL COMPONENTS; CHEMOTHERAPY; GENE; GENE EXPRESSION; GENETIC ENGINEERING; RNA; RODENT; SECRETION; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DNA DAMAGE; ENDOTHELIUM CELL; GENE; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; PROTEIN EXPRESSION; REGULATORY MECHANISM; TREX1 GENE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; BAGG ALBINO MOUSE; DOWN REGULATION; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; RADIATION RESPONSE; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

MUS;

ANIMALS; CELL LINE, TUMOR; DOWN-REGULATION; EXODEOXYRIBONUCLEASES; FAS RECEPTOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHOPROTEINS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RNA, SMALL INTERFERING; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84999035231     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms13597     Document Type: Article

References (43)

1. Economopoulou, M. et al. Histone H2AX is integral to hypoxia-driven neovascularization. Nat. Med. 15, 553-558 (2009).
2. Okuno, Y., Nakamura-Ishizu, A., Otsu, K., Suda, T. & Kubota, Y. Pathological neoangiogenesis depends on oxidative stress regulation by ATM. Nat. Med. 18, 1208-1216 (2012).
3. Garcia-Barros, M. et al. Tumour response to radiotherapy regulated by endothelial cell apoptosis. Science 300, 1155-1159 (2003).
4. Paris, F. et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293, 293-297 (2001).
5. Landskroner-Eiger, S., Moneke, I. & Sessa, W. C. miRNAs as modulators of angiogenesis. Cold Spring Harb. Perspect. Med. 3, a006643 (2013).
6. Nakatsu, M. N. & Hughes, C. C. An optimized three-dimensional in vitro model for the analysis of angiogenesis. Methods Enzymol. 443, 65-82 (2008).
7. Aguilar, E. et al. Chapter 6. Ocular models of angiogenesis. Methods Enzymol. 444, 115-158 (2008).
8. Grothey, A. & Galanis, E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat. Rev. Clin. Oncol. 6, 507-518 (2009).
9. Lee, J. J. & Chu, E. Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer. Clin. Colorectal Cancer 13, 135-144 (2014).
10. Dimberg, A. The glioblastoma vasculature as a target for cancer therapy. Biochem. Soc. Trans. 42, 1647-1652 (2014).
11. Xue, W. et al. Small RNA combination therapy for lung cancer. Proc. Natl Acad. Sci. USA 111, E3553-E3561 (2014).
12. Dahlman, J. E. et al. In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight. Nat. Nanotechnol. 9, 648-655 (2014).
13. Pàez-Ribes, M. et al. Antiangiogenic therapy elicits malignant progression of tumours to increased local invasion and distant metastasis. Cancer Cell 15, 220-231 (2009).
14. Ebos, J. M. L. et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumour angiogenesis. Cancer Cell 15, 232-239 (2009).
15. Bartel, D. P. MicroRNAs: target recognition and regulatory functions. Cell 136, 215-233 (2009).
16. Crow, Y. J. et al. Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 cause Aicardi-Goutieres syndrome at the AGS1 locus. Nat. Genet. 38, 917-920 (2006).
17. Lee-Kirsch, M. A. et al. Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat. Genet. 39, 1065-1067 (2007).
18. Richards, A. et al. C-terminal truncations in human 3′-5′ DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat. Genet. 39, 1068-1070 (2007).
19. Kavanagh, D. et al. New roles for the major human 3′-5′ exonuclease TREX1 in human disease. Cell Cycle 7, 1718-1725 (2008).
20. Cambronne, X. A., Shen, R., Auer, P. L. & Goodman, R. H. Capturing microRNA targets using an RNA-induced silencing complex (RISC)-trap approach. Proc. Natl Acad. Sci. USA 109, 20473-20478 (2012).
21. Yan, N., Regalado-Magdos, A. D., Stiggelbout, B., Lee-Kirsch, M. A. & Lieberman, J. The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat. Immunol. 11, 1005-1013 (2010).
22. Yang, Y. G., Lindahl, T. & Barnes, D. E. Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmune disease. Cell 131, 873-886 (2007).
23. Hasan, M. et al. Cytosolic nuclease TREX1 regulates oligosaccharyl transferase activity independent of nuclease activity to suppress immune activation. Immunity 43, 463-474 (2015).
24. Angiolillo, A. L. et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J. Exp. Med. 182, 155-162 (1995).
25. Bodnar, R. J., Yates, C. C. & Wells, A. IP-10 blocks vascular endothelial growth factor-induced endothelial cell motility and tube formation via inhibition of calpain. Circ. Res. 98, 617-625 (2006).
26. Bodnar, R. J., Yates, C. C., Rodgers, M. E., Du, X. & Wells, A. IP-10 induces dissociation of newly formed blood vessels. J. Cell Sci. 122, 2064-2077 (2009).
27. Weiss, J. M., Subleski, J. J., Wigginton, J. M. & Wiltrout, R. H. Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin. Biol. Ther. 7, 1705-1721 (2007).
28. Ruffell, B., Affara, N. I. & Coussens, L. M. Differential macrophage programming in the tumour microenvironment. Trends Immunol. 33, 119-126 (2012).
29. Martello, G. et al. A microRNA targeting dicer for metastasis control. Cell 141, 1195-1207 (2010).
30. Trajkovski, M. et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 474, 649-653 (2011).
31. Garofalo, M. et al. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat. Med. 18, 74-82 (2012).
32. Huang, J. W. et al. Systematic screen identifies miRNAs that target RAD51 and RAD51D to enhance chemosensitivity. Mol. Cancer Res. 11, 1564-1573 (2013).
33. Chen, Z. et al. Hypoxia-responsive miRNAs target argonaute 1 to promote angiogenesis. J. Clin. Invest. 123, 1057-1067 (2013).
34. Chabot, S. et al. A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor. J. Exp. Med. 208, 973-986 (2011).
35. Miyazaki, T. et al. The 3′-5′ DNA exonuclease TREX1 directly interacts with poly(ADP-ribose) polymerase-1 (PARP1) during the DNA damage response. J. Biol. Chem. 289, 32548-32558 (2014).
36. Yuan, F. et al. Human DNA exonuclease TREX1 is also an exoribonuclease that acts on single-stranded RNA. J. Biol. Chem. 290, 13344-13353 (2015).
37. Grieves, J. L. et al. Exonuclease TREX1 degrades double-stranded DNA to prevent spontaneous lupus-like inflammatory disease. Proc. Natl Acad. Sci. USA 112, 5117-5122 (2015).
38. Peschke, K. et al. Deregulated type I IFN response in TREX1-associated familial chilblain lupus. J. Invest. Dermatol. 134, 1456-1459 (2014).
39. Pereira-Lopes, S. et al. The exonuclease Trex1 restrains macrophage proinflammatory activation. J. Immunol. 191, 6128-6135 (2013).
40. Hanahan, D. & Coussens, L. M. Accessories to the crime: functions of cells recruited to the tumour microenvironment. Cancer Cell 21, 309-322 (2012).
41. Fokas, E., McKenna, W. G. & Muschel, R. J. The impact of tumour microenvironment on cancer treatment and its modulation by direct and indirect antivascular strategies. Cancer Metastasis Rev. 31, 823-842 (2012).
42. Pena, J. T. et al. miRNA in situ hybridization in formaldehyde and EDC-fixed tissues. Nat. Methods 6, 139-141 (2009).
43. Scheppke, L. et al. Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits. J. Clin. Invest. 118, 2337-2346 (2008).